Ad Code: Erleada - Display Banners Condition Spotlight - 102902

Only half of patients with metastatic castration-resistant prostate cancer were tested for HRR mutations, and PARP inhibitors were underused.

Men with metastatic hormone-sensitive prostate cancer who experience baseline bone pain have worse survival outcomes despite treatment intensification.

Various sessions at the 2024 ASCO Genitourinary Cancers Symposium reviewed health care discrimination and disparities among patients with prostate cancer.

Researchers emphasized the importance of bone-protective agents in patients treated for metastatic castration-resistant prostate cancer.

Researchers found correlations between PSMA PET total tumor burden and survival in patients with high-volume metastatic hormone-sensitive prostate cancer.

The following is a summary of “Prognostic utility of RECIP 1.0 with manual and AI-based...

An analysis of 12 clinical trials shows no difference in mortality risk with continuous versus intermittent androgen deprivation therapy for prostate cancer.

Both Black and White patients with metastatic castration-sensitive prostate cancer (mCSPC) showed similar progression-free survival and overall survival in a clinical trial setting.

The following is a summary of “BRCA-deficient metastatic prostate cancer has an adverse...

In metastatic castration-sensitive prostate cancer, patients on apalutamide were 53% more likely...

Routine conversations about costs can address the financial toxicity associated with new...